Adiponectin and adiponectin receptors - PubMed (original) (raw)
Review
Adiponectin and adiponectin receptors
Takashi Kadowaki et al. Endocr Rev. 2005 May.
Abstract
Metabolic syndrome is thought to result from obesity and obesity-linked insulin resistance. Obesity in adulthood is characterized by adipocyte hypertrophy. Adipose tissue participates in the regulation of energy homeostasis as an important endocrine organ that secretes a number of biologically active "adipokines."Heterozygous peroxisome proliferator-activated receptor-gamma knockout mice were protected from high-fat diet induced obesity, adipocyte hypertrophy, and insulin resistance. Systematic gene profiling analysis of these mice revealed that adiponectin/Acrp30 was overexpressed. Functional analyses including generation of adiponectin transgenic or knockout mice have revealed that adiponectin serves as an insulin-sensitizing adipokine. In fact, obesity-linked down-regulation of adiponectin was a mechanism whereby obesity could cause insulin resistance and diabetes. Recently, we have cloned adiponectin receptors in the skeletal muscle (AdipoR1) and liver (AdipoR2), which appear to comprise a novel cell-surface receptor family. We showed that AdipoR1 and AdipoR2 serve as receptors for globular and full-length adiponectin and mediate increased AMP-activated protein kinase, peroxisome proliferator-activated receptor-alpha ligand activities, and glucose uptake and fatty-acid oxidation by adiponectin. Obesity decreased expression levels of AdipoR1/R2, thereby reducing adiponectin sensitivity, which finally leads to insulin resistance, the so-called "vicious cycle." Most recently, we showed that osmotin, which is a ligand for the yeast homolog of AdipoR (PHO36), activated AMPK via AdipoR in C2C12 myocytes. This may facilitate efficient development of adiponectin receptor agonists. Adiponectin receptor agonists and adiponectin sensitizers should serve as versatile treatment strategies for obesity-linked diseases such as diabetes and metabolic syndrome.
Similar articles
- Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
Yamauchi T, Kadowaki T. Yamauchi T, et al. Int J Obes (Lond). 2008 Dec;32 Suppl 7:S13-8. doi: 10.1038/ijo.2008.233. Int J Obes (Lond). 2008. PMID: 19136982 Review. - Adiponectin--a key adipokine in the metabolic syndrome.
Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Whitehead JP, et al. Diabetes Obes Metab. 2006 May;8(3):264-80. doi: 10.1111/j.1463-1326.2005.00510.x. Diabetes Obes Metab. 2006. PMID: 16634986 Review. - Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Kadowaki T, et al. J Clin Invest. 2006 Jul;116(7):1784-92. doi: 10.1172/JCI29126. J Clin Invest. 2006. PMID: 16823476 Free PMC article. Review. - Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
Goto T, Teraminami A, Lee JY, Ohyama K, Funakoshi K, Kim YI, Hirai S, Uemura T, Yu R, Takahashi N, Kawada T. Goto T, et al. J Nutr Biochem. 2012 Jul;23(7):768-76. doi: 10.1016/j.jnutbio.2011.04.001. Epub 2011 Sep 1. J Nutr Biochem. 2012. PMID: 21889885 - Adiponectin-Resistance in Obesity.
Engin A. Engin A. Adv Exp Med Biol. 2017;960:415-441. doi: 10.1007/978-3-319-48382-5_18. Adv Exp Med Biol. 2017. PMID: 28585210 Review.
Cited by
- Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.
Dongiovanni P, Anstee QM, Valenti L. Dongiovanni P, et al. Curr Pharm Des. 2013;19(29):5219-38. doi: 10.2174/13816128113199990381. Curr Pharm Des. 2013. PMID: 23394097 Free PMC article. - Decreased adiponectin level is associated with aggressive phenotype of tongue squamous cell carcinoma.
Guo XH, Wang JY, Gao Y, Gao M, Yu GY, Xiang RL, Li L, Yang NY, Cong X, Xu XY, Li SL, Peng X, Wu LL. Guo XH, et al. Cancer Sci. 2013 Feb;104(2):206-13. doi: 10.1111/cas.12077. Epub 2013 Jan 20. Cancer Sci. 2013. PMID: 23181352 Free PMC article. - Clinical characteristics and treatment compounds of obesity-related kidney injury.
Mao TH, Huang HQ, Zhang CH. Mao TH, et al. World J Diabetes. 2024 Jun 15;15(6):1091-1110. doi: 10.4239/wjd.v15.i6.1091. World J Diabetes. 2024. PMID: 38983811 Free PMC article. Review. - Metabolic syndrome, obesity, and gastrointestinal cancer.
Fujihara S, Mori H, Kobara H, Nishiyama N, Kobayashi M, Oryu M, Masaki T. Fujihara S, et al. Gastroenterol Res Pract. 2012;2012:483623. doi: 10.1155/2012/483623. Epub 2012 Dec 11. Gastroenterol Res Pract. 2012. PMID: 23304125 Free PMC article. - Endoplasmic reticulum (ER) localization is critical for DsbA-L protein to suppress ER stress and adiponectin down-regulation in adipocytes.
Liu M, Chen H, Wei L, Hu D, Dong K, Jia W, Dong LQ, Liu F. Liu M, et al. J Biol Chem. 2015 Apr 17;290(16):10143-8. doi: 10.1074/jbc.M115.645416. Epub 2015 Mar 4. J Biol Chem. 2015. PMID: 25739441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous